Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Takeda
Celgene
Novartis
Pfizer
AbbVie
Takeda
Pfizer
Novartis
Celgene
Eli Lilly and Company
Il-Yang Pharm. Co., Ltd.
AbbVie
Hoffmann-La Roche
Jazz Pharmaceuticals
Amgen
Hoffmann-La Roche
Il-Yang Pharm. Co., Ltd.
Merck Sharp & Dohme LLC
Teva Branded Pharmaceutical Products R&D, Inc.
AstraZeneca
Antisoma Research
Amgen
Kanisa Pharmaceuticals
Kanisa Pharmaceuticals